Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Jongmans who wrote (240)	2/5/1998 2:39:00 PM
From: HB	Read Replies (1) \| Respond to of 4474

So, presumably the hit is due to the increased losses... cash/loss rate = 6 quarters at last quarter's rate. Increased expenses and reduced revenues both contributed. Probably just noise... (Is this what's usually referred to as the burn rate, or is burn rate just the absolute value of cash flow...are the 2 close in this case?) Looks like $4 will buy you $1/share/year of ARIAD's R&D spending, based on last fiscal year. Seems like a decent deal to me... comments? biz.yahoo.com Howard